Curis Articles
Positive CHMP recommendations for Astellas Xtandi, Roche's Erivedge, as well MACI, Nuedexta and Spedra
28 April 2013
Curis in-licenses cancer candidate from Genentech
30 November 2012
Faster-than-expected FDA approval of Roche’s vismodegib
31 January 2012
FDA priority review for Roche/Genentech’s vismodegib for skin cancer
10 November 2011
Roche tells Curis that Ph II data on GDC-0449 in advanced ovarian cancer needs additional investigation
10 August 2010
Curis shares plummet as “Hedgehog” drug being developed with Roche fails in colorectal cancer trial
17 June 2010
Showing 1-9 of 9 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
